Home › Prostate Cancer › North Carolina
Prostate Cancer clinical trials in North Carolina
47 studies for Prostate Cancer are looking for participants at sites in North Carolina.
Cities in North Carolina
- Durham32 studies
- Charlotte7 studies
- Winston-Salem5 studies
- Concord5 studies
- Asheville3 studies
- New Bern3 studies
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- ECU Health Oncology Kinston, Kinston
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 13, 2026 · NCT04423211Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT05691465Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Duke University Medical Center Duke Cancer Center, Durham
RecruitingPhase 1
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT04221542Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Associated Urologists of North Carolina (AUNC), Raleigh
Recruiting
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT06511141Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
- Duke University Medical Center, Durham
Recruiting
Ages 18 and older · Men · Updated Nov 6, 2026 · NCT07685249The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
- Duke University Medical Center, Durham
RecruitingObservational study
Ages 18 and older · Men · Updated Nov 6, 2026 · NCT06141993Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Levine Cancer Institute, Charlotte
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 5, 2026 · NCT07745361Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
- Duke University, Durham
RecruitingObservational study
Ages 40 and older · Men · Updated Nov 4, 2026 · NCT07144228Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- and 6 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06632977A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Urology Specialists of the Carolinas - University Place, Charlotte
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07723248A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Atrium Health Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT06095089Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT06931340Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Duke University Medical Center, Durham
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT06800313Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Durham VA Medical Center, Durham
- CarolinaEast Medical Center, New Bern
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 23, 2026 · NCT05946213A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- Duke Cancer Center, Durham
RecruitingPhase 1
Ages 18 and older · Men · Updated Oct 20, 2026 · NCT07103018This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Duke Cancer Center Cary, Cary
- Duke University Medical Center (location of scans), Durham
- Duke University Medical Center - Duke Cancer Center, Durham
- and 5 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 14, 2026 · NCT07028853Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- and 7 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 8, 2026 · NCT03678025FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Duke University, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Durham VA Medical Center, Durham, NC, Durham
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT05011383Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Durham VA Medical Center, Durham, NC, Durham
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT04038502Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT07493512Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Duke University Medical Center, Durham
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT06056830COMPASS Study for Metastatic Castration-resistant Prostate Cancer
- Duke University, Durham
RecruitingObservational study
Ages 18 and older · Men · Updated Aug 27, 2026 · NCT07050433A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- Duke University medical center, Durham
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Aug 20, 2026 · NCT06785636A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Duke University Medical Center - Duke Cancer Center, Durham
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 17, 2026 · NCT06842498A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT06067841A Study of DM002 in Patients With Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health University City/LCI-University, Charlotte
- Levine Cancer Institute-Ballantyne, Charlotte
- and 9 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 14, 2026 · NCT06592924Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · Men · Updated Jul 9, 2026 · NCT05413421Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
- Duke University, Durham
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Jun 25, 2026 · NCT06457919Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07463833Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- W.G. Bill Hefner Medical Center, Salisbury
RecruitingPhase 2
Ages 18 and older · Men · Updated Jun 15, 2026 · NCT05422911Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
- Duke University Medical Center, Durham
RecruitingPhase 4
Ages 18 to 100 · Men · Updated Jun 4, 2026 · NCT05803941From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.